User:Mac/Agenda

18 Jan 2010

Notes

• write 1 paragraph / section of paper outline (now in Field Definition)

• track down a ton of papers from the bibliographies of Legal uncertainty in the area of genetic diagnostic testing and Genome patents and personalized medicine - what lies ahead?
  • add the above to the bibliography
• read chapter 20, Gene patents: from discovery to invention from Gene Patents and Collaborative Licensing Models
  • add the above to the bibliography
• read a bunch of other papers I printed

11 Jan 2010

Notes

• Got Misha's Feedback
  • read this: College of American Pathologists POET report on IVDMIAs
  • And this: market report w/r/t multivariate testing (at least the table of contents)
• Get Annual Reports from key companies listed; summarize
• Add papers about GDx reference materials from Journal of Molecular Diagnostics
• add profiles of major Personal Genomics companies to Overall Picture of Kits Sector

2 Dec 2009 TODO

Notes

• add GDx / PGx from SACGHS appendix and PGx paper to the case studies (~15?)
  • Add OTC genetic tests to the list
  • move to no.2, overall picture of kits

• write 1 paragraph / section of paper outline

• centralize answers to "do patents harm researchers?"

• complete field definition - 1st draft
  • complete data, narratives, tools defn, build off of Ford report section
    • get basic market stats / picture (just GDx) - partial; just national ref labs

• read last chapter's of Gene Cartels
• read SACGHS Report final draft
• back up the following statements with data (in particular, "But the vast majority of gene patents are obtained by universities and unlicensed, or by companies and unprosecuted.")
  • http://cyber.law.harvard.edu/commonsbasedresearch/?title=Diagnostic_Kits/The_Argument_Framework&direction=next&oldid=4910

Duke team, Luigi interview

• come up w/ questions
• position on IVDMIAs
• use interview framework from EM

Identify people to ask about IVDMIA tests

• look at federal docket of comments in response to draft guideline
• ask the 5 OTC companies in interview